Press Releases

SOUTH SAN FRANCISCO, California (GLOBE NEWSWIRE)—MyoKardia, Inc. (Nasdaq:MYOK) (“MyoKardia” or the “Company”), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that additional positive data…
LEXINGTON, Mass., Sept. 14, 2017 — G3 Pharmaceuticals, a newly formed biopharmaceutical company located in Lexington, MA, today announced the start of its research and development program to pursue novel galectin-3 inhibitors.   Galectin-3 is a protein that is responsible for fibrosis forming in…
THOUSAND OAKS, Calif., Sept. 15, 2017 — Amgen (NASDAQ:AMGN) today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels with Repatha® (evolocumab) significantly and consistently reduced…
September 14, 2017 — A global team of researchers reported in the New England Journal of Medicine that the study did not meet its primary efficacy endpoint, but yielded important results for all-cause mortality.Diabetes is a widespread and increasing problem currently affecting 30.3 million…
ATLANTA, Sept. 14, 2017 (GLOBE NEWSWIRE)—Zywie, a health IT company using technology to improve the early detection and precise remote monitoring of patients with cardiovascular disease (CVD), has been selected to participate in the Startup Showcase at the 2017 Venture Atlanta. The 10th annual…
DUBLIN and LAS VEGAS — September 12, 2017 — Medtronic plc (NYSE: MDT) data announced today reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The two-year, real-world results from the full clinical…
DUBLIN — September 8, 2017 — Medtronic plc (NYSE: MDT) today announced that the IN.PACT(TM)Admiral(TM) Drug-Coated Balloon (DCB) received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of peripheral artery disease (PAD) in the upper leg - specifically…
The Food and Drug Administration (FDA) has cleared TrueFusion, a new cardiovascular application from Siemens Healthineers that integrates ultrasound and angiography images to guide cardiac teams when administering treatment for structural heart disease. Available on the new Release 5.0 of the…
ABBOTT PARK, Ill., Aug. 30, 2017 — Abbott (NYSE: ABT) today announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified version of its AMPLATZER™ device designed to correct a common congenital heart defect that occurs in approximately 80,000 pre…
DANVERS, Mass., Aug. 28, 2017 — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has accepted the resignation of its Chief Financial Officer, Michael Tomsicek, effective August 24, 2017. After two years, Mr. Tomsicek…
ABBOTT PARK, Ill., Aug. 28, 2017 — Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev™ HeartMate 3™ Left Ventricular Assist System (also known as an LVAD). The HeartMate 3 system provides a new option for physicians managing…
MURRAY HILL, N.J. — August 28, 2017 — C. R. Bard, Inc. (NYSE:BCR) today announced the LUTONIX® 035 Drug Coated Balloon PTA Catheter (DCB) has been granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA) for a new indication and is now available for sale in the United…
August 24, 2017 — AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) from treatment with Brilinta (ticagrelor) 60mg twice daily, versus placebo, in patients taking lowdose aspirin…
DUBLIN - August 22, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2018, which ended July 28, 2017.The company reported first quarter worldwide revenue of $7.390 billion, compared to the $7.166 billion reported in the first quarter of…
DUBLIN - August 21, 2017 - Medtronic plc (NYSE: MDT) announced it has received CE (Conformité Européene) Mark for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators (CRT-D) and -pacemakers (CRT-P),…
WESTLAKE, Texas, Aug. 17, 2017 — HeartSciences today announced the European launch of MyoVista® high sensitivity electrocardiograph (hsECG™) Testing Device, developed in response to the global unmet need for effective, low-cost, front-line screening of cardiac disease in both symptomatic and…
Seattle, Wash. – August 15, 2017 – Today, angelMD and the American College of Cardiology (ACC) announced a new partnership to promote engagement of cardiovascular clinicians in health care innovation and entrepreneurship. The agreement seeks to increase the exchange of knowledge in cultivating,…
MOUNTAIN VIEW, Calif.-- (August 15, 2017) --Vascular Dynamics, Inc., (VDI) a privately held medical device company developing novel solutions for the treatment of hypertension, today announces that the United States Food and Drug Administration (FDA) has approved the company’s Investigational…
ST. LOUIS, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2017.David Fischel, Chairman and Acting CEO, commented…
MINNEAPOLIS, MN, August 9, 2017 – Minneapolis Heart Institute Foundation® announced it has enrolled the first-in-the-world patient in a clinical study to evaluate a minimally invasive clip-based repair system made by Abbott (a company based near Chicago), for treating people with moderate or…
DUBLIN - July 30, 2017 - Medtronic plc (NYSE: MDT) today announced that it has completed the previously announced sale of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional Insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally…